Your browser doesn't support javascript.
COVID-19 therapeutics: Challenges and directions for the future.
Robinson, Philip C; Liew, David F L; Tanner, Helen L; Grainger, John R; Dwek, Raymond A; Reisler, Ronald B; Steinman, Lawrence; Feldmann, Marc; Ho, Ling-Pei; Hussell, Tracy; Moss, Paul; Richards, Duncan; Zitzmann, Nicole.
  • Robinson PC; Faculty of Medicine, University of Queensland School of Clinical Medicine, Herson, QLD 4006, Australia.
  • Liew DFL; Metro North Hospital & Health Service, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia.
  • Tanner HL; Department of Medicine, University of Melbourne, Melbourne, VIC 3010, Australia.
  • Grainger JR; Department of Rheumatology, Austin Health, Melbourne, VIC 3084, Australia.
  • Dwek RA; Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, VIC 3084, Australia.
  • Reisler RB; Faculty of Medicine, University of Queensland School of Clinical Medicine, Herson, QLD 4006, Australia.
  • Steinman L; Metro North Hospital & Health Service, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia.
  • Feldmann M; Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester M13 9PL, United Kingdom.
  • Ho LP; Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 2JD, United Kingdom.
  • Hussell T; Medical Division, Davis Defense Group, Stafford, VA 22554.
  • Moss P; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.
  • Richards D; Department of Pediatrics, Stanford University, Stanford, CA 94305.
  • Zitzmann N; Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom.
Proc Natl Acad Sci U S A ; 119(15): e2119893119, 2022 04 12.
Article in English | MEDLINE | ID: covidwho-1778688
ABSTRACT
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the greatest medical emergency of the last century. COVID-19 has highlighted health disparities both within and between countries and will leave a lasting impact on global society. Nonetheless, substantial investment in life sciences over recent decades has facilitated a rapid scientific response with innovations in viral characterization, testing, and sequencing. Perhaps most remarkably, this permitted the development of highly effective vaccines, which are being distributed globally at unprecedented speed. In contrast, drug treatments for the established disease have delivered limited benefits so far. Innovative and rapid approaches in the design and execution of large-scale clinical trials and repurposing of existing drugs have saved many lives; however, many more remain at risk. In this review we describe challenges and unmet needs, discuss existing therapeutics, and address future opportunities. Consideration is given to factors that have hindered drug development in order to support planning for the next pandemic challenge and to allow rapid and cost-effective development of new therapeutics with equitable delivery.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article Affiliation country: Pnas.2119893119

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pandemics / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Proc Natl Acad Sci U S A Year: 2022 Document Type: Article Affiliation country: Pnas.2119893119